What Did You Forget to Put in Your Strategy?
Most biotech founders don't fail because the science is weak.
They fail because of what wasn't in the strategy at all.
You've built something real, the science is solid, the team is committed - but somewhere between the lab and the market ... something is missing.
Not wrong! - missing.
And the hardest part is you can't see it from the inside.
Introducing The Blind Spot A free, private strategic assessment for early-stage biotech founders.
This is not a quiz. There is no automated score. No generic report generated by an algorithm.
You answer seven questions about your company — in your own words. Attila reads every submission personally. Then you meet one-on-one online for a focused strategic session where the real diagnosis happens.
You leave knowing exactly what your strategy is missing — and what to do about it.
Why Most Biotech Strategies Stall? — And It's Not the Science
After working with early-stage biotech founders from pre-seed to Series B, the pattern is always the same.
The science is credible. The founder is sharp. But the strategy has gaps nobody has named out loud yet.
The investor narrative sounds too academic. The milestone map tracks R&D but doesn't signal business value. The commercial logic hasn't been built yet. The team gap nobody wants to talk about is growing quietly in the background.
These are not small problems. They are the problems that kill fundable companies.
The Blind Spot finds them before they find you.
What We Look At?
Seven areas where biotech strategies most commonly break down — and where the most important blind spots hide.
1. Your strategy and vision Where is the company going in the next 5–10 years — and does the plan hold up when a skeptical investor pushes back?
2. Your market and urgency Who needs what you're building — and why do they act now, not in three years?
3. Your milestones What do your next 3–5 milestones unlock for the business — not just for the R&D calendar?
4. Your cash flow and runway How are you managing burn — and what breaks first if your funding assumptions are wrong?
5. Your team and organization What's the gap between the team you have today and the company you're building in the next 2–3 years?
6. Your science as a system Can you explain the core idea clearly enough for a smart non-scientist to act on it?
7. Your external perception What do investors, partners, and potential customers actually think about your company right now — not what you hope they think?
How The Blind Spot Works?
Step 1 — Reserve your spot A limited number of sessions are available each month. This is not a webinar. Not a group call. It is a private, focused session with Attila — reserved for founders who are serious about finding what's missing.
Step 2 — Receive the questions You'll get an email with seven open-ended questions and a short NDA. No word limits. No templates. Answer the way you think.
Step 3 — Attila reads your answers Every submission is read personally before the session. No algorithms. No automation. When you show up to the meeting the diagnosis has already started.
Step 4 — The live session One hour online. Direct questions. Honest answers. The conversation goes where it needs to go — not where it's comfortable.
Step 5 — You receive the full session notes Captured by Fathom and sent to you after the meeting. Everything discussed, nothing lost.
This Is Not for Every Biotech Founder
The Blind Spot is for early-stage biotech founders — pre-seed to Series B — who are building serious science and are honest enough to ask what the strategy is missing.
It is not for founders who want validation. It is not for teams that aren't ready for a direct conversation. It is not a sales call dressed up as a free assessment.
If you want someone to tell you everything looks good — this is the wrong session.
If you want to know what you haven't thought about — you're in the right place.
What Happens After The Blind Spot?
Body Some founders leave the session with clarity they can act on immediately. Others realise the gaps are bigger than they thought — and want to go deeper.
If that's the case, Timeline Strategy offers two ways to keep working together.
The Sprint — a focused strategic engagement to fix what's missing and build the business layer your science deserves.
The Partnership — ongoing strategic support for founders who need a thinking partner on the business side, not another vendor.
There is no pressure. No pitch. The session speaks for itself.
Who Reads Your Answers?
I'm Attila Foris, founder of Timeline Strategy BioTech.
I work with early-stage biotech founders who are building serious science but need sharper strategy on the business side — positioning, investor narrative, milestones, partnerships, commercial logic, organisation.
Before Timeline Strategy, I've sat on both sides of the table — building the business case from inside biotech companies and evaluating them from the outside.
The Blind Spot exists because I've seen too many fundable companies stall on problems nobody named early enough. This is the conversation I wish more founders had before they raised, before they pitched, before they hired.
If your company is serious and you're honest about wanting a direct conversation — reserve a spot.
Reserve Your Blind Spot Session
A small number of spots are available each month.
This is a private, one-on-one strategic session with Attila Foris — founder of Timeline Strategy BioTech and strategic partner to early-stage biotech founders.
No slides. No sales sequence. Just an honest conversation about what your strategy is missing.
- Free.
- Private.
- Limited availability.
Attila reads every submission personally before the session.